All
FDA Approves Lonsurf Plus Avastin for Metastatic Colorectal Cancer
August 2nd 2023The Food and Drug Administration has approved the combination of Lonsurf and Avastin for patients with metastatic colorectal cancer previously treated with chemotherapies, an anti-VEGF therapy and, if RAS wild-type, an anti-EGFR therapy.
Weekly Fosaprepitant Betters Quality of Life During Chemoradiotherapy
August 2nd 2023Patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy reported higher quality of life and were less likely to experience vomiting when receiving fosaprepitant every week as opposed to every three weeks.